The Effect Of Once-weekly Subcutaneous Semaglutide On Functional Capacity In People With Type 2 Diabetes And Peripheral Artery Disease: PrimaryResults From The Phase 3b, Randomized, Placebo-controlled, Double Blind Stride Trial